Submitted by Anonymous (not verified) on 10 March 2026 - 12:37
Opinion/decision on a Paediatric investigation plan (PIP): Trodelvy, sacituzumab govitecan, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: EMA/PE/0000228097
Source: